The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
iTeos Therapeutics, Inc(NASDAQ:ITOS) 
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a...
Website: http://www.iteostherapeutics.com
Founded: 2012
Full Time Employees: 55
CEO: Michel Detheux
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
iTeos Therapeutics Days Payable Outstanding ttm (DPO)
iTeos Therapeutics Days Receivable Outstanding ttm (DSO)
iTeos Therapeutics Op Cashflow Per Share ttm
iTeos Therapeutics Free Cashflow Per Share ttm
iTeos Therapeutics Cash Per Share ttm
iTeos Therapeutics P/S ratio ttm
iTeos Therapeutics (GAAP) P/E ratio ttm
iTeos Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.